ISSN 1016-5169 | E-ISSN 1308-4488
After the GEMINI-ACS-1 trial [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2017; 45(4): 8-9 | DOI: 10.5543/tkda.2017.52358

After the GEMINI-ACS-1 trial

Mehmet Birhan Yılmaz
Departmen of Cardiology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey

The GEMINI-ACS-1 trial has recently been published. It was designed to test whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in patients with acute coronary syndromes(ACS). The trial is important to set light to future of ACS management.

Keywords: GEMINI-ACS-1, antithrombotic, acute coronary syndromes

How to cite this article
Mehmet Birhan Yılmaz. After the GEMINI-ACS-1 trial. Turk Kardiyol Dern Ars. 2017; 45(4): 8-9

Corresponding Author: Mehmet Birhan Yılmaz, France
Manuscript Language: Turkish

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 Archives of the Turkish Society of Cardiology

Kare Publishing is a subsidiary of Kare Media.